Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies
The Oncologist · 27.12.2025 · 31 (1)
DOI: 10.1093/oncolo/oyaf396 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 02.12.2025. Verfasst von Yeon Hee Park und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Trastuzumab, Immunoconjugates, Camptothecin, Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Daiichi Sankyo, Inc.
Abstract (Originalsprache)
Background
Trastuzumab deruxtecan (T-DXd), an approved human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugate, may cause treatment-emergent adverse events (TEAEs), most commonly gastrointestinal and hematologic TEAEs. This pooled analysis evaluated TEAEs across 2 doses of T-DXd in patients with different cancers to support safe and effective real-world use. Patients and Methods Data were pooled from 9 phase I-III clinical trials (DS8201-A-J101; DESTINY-Breast01/02/03/04; DESTINY-Lung01/02; DESTINY-Gastric01/02) of T-DXd 5.4 or 6.4 mg/kg every 3 weeks in patients (N = 1678) with metastatic breast, gastric, or lung cancer with varying HER2 expression or HER2 mutation status. Nausea, vomiting, neutropenia, fatigue, and interstitial lung disease (ILD) were evaluated for time to onset and dose-related outcomes. Antiemetic analysis was limited before a 2020 protocol change recommending prophylaxis.
Results
Common TEAEs (in ≥20%) were fatigue, nausea, vomiting, neutropenia, anemia, and thrombocytopenia; mostly grade 1 or 2. TEAEs leading to dose reduction, drug interruption, and discontinuation with T-DXd were 22.6%, 42.8%, and 17.7% (5.4 mg/kg), and 29.7%, 47.6%, and 16.6% (6.4 mg/kg), respectively. Neutropenia, nausea, and fatigue occurred in 34.6%, 74.6%, and 56.5% of patients (5.4 mg/kg) and 49.3%, 65.5%, and 52.8% (6.4 mg/kg). Adjudicated drug-related ILD occurred in 12.0% and 10.9%, respectively.
Conclusion
Gastrointestinal and hematologic TEAEs were most common, with nausea, neutropenia, and fatigue most commonly reported. ILD/pneumonitis occurred in ∼11%-12% of patients, with severe cases infrequent. Most TEAEs were low grade, though dose modifications highlight the need for proactive TEAE management, particularly in older patients and those with renal impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
- IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain.
- Oncology Department, Hospital Universitario Torrejón, Ribera Group, Madrid, Spain.
- Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
- Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City, NJ, United States.
ORCID-Profile: Yeon Hee Park, Giampaolo Bianchini, Hiroji Iwata, Kohei Shitara, Sandra M Swain
Förderung
- NCI NIH HHS
- Daiichi Sankyo, Inc
Zitieren
APA
Park, Y. H., Cortes, J., Modi, S., Hurvitz, S. A., Bianchini, G., Iwata, H., Shitara, K., Siena, S., Goto, Y., Ku, G. Y., Powell, C. A., Swain, S. M., Arunachalam, M., Janek, M., Cheng, Y., Chu, C., Verma, P., Kuptsova-Clarkson, N., Mathias, E., …, & Rugo, H. S. (2025). Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies. The Oncologist, 31(1). https://doi.org/10.1093/oncolo/oyaf396
Vancouver
Park YH, Cortes J, Modi S, Hurvitz SA, Bianchini G, Iwata H, et al. Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies. The Oncologist. 2025;31(1). doi:10.1093/oncolo/oyaf396
BibTeX
@article{Park2025,
author = {Park, Yeon Hee and Cortes, Javier and Modi, Shanu and Hurvitz, Sara A and Bianchini, Giampaolo and Iwata, Hiroji and Shitara, Kohei and Siena, Salvatore and Goto, Yasushi and Ku, Geoffrey Y and Powell, Charles A and Swain, Sandra M and Arunachalam, Meena and Janek, Martin and Cheng, Yingkai and Chu, Changan and Verma, Purnima and Kuptsova-Clarkson, Nataliya and Mathias, Elton and Goodman, Erin and Rugo, Hope S},
title = {Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies},
journal = {The Oncologist},
year = {2025},
volume = {31},
number = {1},
doi = {10.1093/oncolo/oyaf396}
}
EUVIMED